未经批准:他汀类药物对冠状动脉生理的影响尚未得到很好的评估。
UNASSIGNED:作者进行了这项前瞻性研究,以调查冠状动脉血流指数和斑块参数的变化,冠心病(CAD)患者的阿托伐他汀治疗及其相关性。
UNASSIGNED:95例接受阿托伐他汀治疗的中度CAD患者接受了血流储备分数(FFR)的综合生理评估,冠状动脉血流储备,微循环阻力指数,索引程序中的血管内超声,并在12个月的随访中接受了相同的评估.最佳低密度脂蛋白胆固醇(LDL-C)定义为LDL-C<70mg/dL或比基线降低≥50%。主要终点是FFR的变化。
未经评估:基线FFR,最小管腔面积,和动脉粥样硬化体积百分比(PAV)分别为0.88±0.05、3.87±1.28、55.92±7.30。在12个月内,LDL-C的百分比变化为-33.2%,而FFR无变化(12个月时为0.87±0.06;P=0.694)。Vesselarea,管腔面积,PAV明显下降(P值均<0.05)。达到的LDL-C水平和PAV的变化与FFR的变化呈显着的负相关。在具有最佳LDL-C修饰的患者中,FFR升高(0.87±0.06vs0.89±0.07;P=0.014),PAV降低(56.81±6.44%vs55.18±8.19%;P=0.031),而在所有其他患者中,FFR降低(0.88±0.05vs0.86±0.06;P=0.025),PAV保持不变.
未经证实:在CAD患者中,尽管PAV降低,但阿托伐他汀并未改变FFR.然而,在阿托伐他汀达到最佳LDL-C目标水平的患者中,随着PAV的降低,FFR显著升高.阿托伐他汀对冠心病血流储备分数的影响[FORTE];NCT01946815。
UNASSIGNED: The effects of statin on coronary physiology have not been well evaluated.
UNASSIGNED: The authors performed this prospective study to investigate changes in coronary flow indexes and plaque parameters, and their associations with atorvastatin therapy in patients with coronary artery disease (CAD).
UNASSIGNED: Ninety-five patients with intermediate CAD who received atorvastatin therapy underwent comprehensive physiological assessments with fractional flow reserve (FFR), coronary flow reserve, index of microcirculatory resistance, and intravascular ultrasound at the index procedure, and underwent the same evaluations at 12-month follow-up. Optimal low-density lipoprotein cholesterol (LDL-C) was defined as LDL-C <70 mg/dL or ≥50% reduction from the baseline. The primary endpoint was a change in the FFR.
UNASSIGNED: Baseline FFR, minimal lumen area, and percent atheroma volume (PAV) were 0.88 ± 0.05, 3.87 ± 1.28, 55.92 ± 7.30, respectively. During 12 months, the percent change in LDL-C was -33.2%, whereas FFR was unchanged (0.87 ± 0.06 at 12 months; P = 0.694). Vessel area, lumen area, and PAV were significantly decreased (all P values <0.05). The achieved LDL-C level and the change of PAV showed significant inverse correlations with the change in FFR. In patients with optimally modified LDL-C, the FFR had increased (0.87 ± 0.06 vs 0.89 ± 0.07; P = 0.014) and the PAV decreased (56.81 ± 6.44% vs 55.18 ± 8.19%; P = 0.031), whereas in all other patients, the FFR had decreased (0.88 ± 0.05 vs 0.86 ± 0.06; P = 0.025) and the PAV remained unchanged.
UNASSIGNED: In patients with CAD, atorvastatin did not change FFR despite a decrease in the PAV. However, in patients who achieved the optimal LDL-C target level with atorvastatin, the FFR had significantly increased with decrease of the PAV. (Effect of Atorvastatin on Fractional Flow Reserve in Coronary Artery Disease [FORTE]; NCT01946815).